Phreesia Management
Management criteria checks 2/4
Phreesia's CEO is Chaim Indig, appointed in Jan 2005, has a tenure of 19.83 years. total yearly compensation is $8.27M, comprised of 6% salary and 94% bonuses, including company stock and options. directly owns 2.25% of the company’s shares, worth $24.10M. The average tenure of the management team and the board of directors is 3.8 years and 17.1 years respectively.
Key information
Chaim Indig
Chief executive officer
US$8.3m
Total compensation
| CEO salary percentage | 6.0% |
| CEO tenure | 19.8yrs |
| CEO ownership | 2.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 17.1yrs |
Recent management updates
Recent updates
Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues
Nov 07
Is Phreesia (NYSE:PHR) Weighed On By Its Debt Load?
Oct 08Here's What Analysts Are Forecasting For Phreesia, Inc. (NYSE:PHR) After Its Second-Quarter Results
Sep 06Phreesia: Remain Bullish Given The Healthy Growth Outlook
Sep 05Market Participants Recognise Phreesia, Inc.'s (NYSE:PHR) Revenues Pushing Shares 26% Higher
Jul 18Phreesia: Growth Remains Strong, With EBITDA Margin Set To Improve
Jun 06The Price Is Right For Phreesia, Inc. (NYSE:PHR)
May 25Are Investors Undervaluing Phreesia, Inc. (NYSE:PHR) By 39%?
May 03At US$23.80, Is Phreesia, Inc. (NYSE:PHR) Worth Looking At Closely?
Apr 12Phreesia Continues To Stay Positive On The Business Growth
Apr 03Phreesia: Healthcare Digitization Beneficiary Hampered By Valuation
Mar 01Investors Still Waiting For A Pull Back In Phreesia, Inc. (NYSE:PHR)
Feb 16Phreesia: Remain Buy Rated As The Business Pivot Towards Profitable Growth
Jan 04Is Phreesia Finally Turning The Corner?
Dec 07Does Phreesia (NYSE:PHR) Have A Healthy Balance Sheet?
Oct 25Phreesia: Share Price Dip Is A Buying Opportunity
Sep 21Phreesia: Strong Execution Should Continue To Drive Growth
Jul 11Phreesia, Inc.'s (NYSE:PHR) Share Price Matching Investor Opinion
May 18Phreesia: Strong Growth Momentum With Expanded TAM
Jan 28Phreesia - Healthcare Ecosystem At An Attractive Valuation
Dec 13Phreesia Q3 2023 Earnings Preview
Dec 07Phreesia GAAP EPS of -$0.89 beats by $0.08, revenue of $67.9M beats by $2.15M
Sep 07Phreesia: Their Time Has Passed
May 10Opportunistic Time To Buy Phreesia's Healthcare Disruption
Dec 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -US$100m |
| Apr 30 2024 | n/a | n/a | -US$119m |
| Jan 31 2024 | US$8m | US$495k | -US$137m |
| Oct 31 2023 | n/a | n/a | -US$144m |
| Jul 31 2023 | n/a | n/a | -US$152m |
| Apr 30 2023 | n/a | n/a | -US$162m |
| Jan 31 2023 | US$8m | US$515k | -US$176m |
| Oct 31 2022 | n/a | n/a | -US$185m |
| Jul 31 2022 | n/a | n/a | -US$181m |
| Apr 30 2022 | n/a | n/a | -US$158m |
| Jan 31 2022 | US$9m | US$515k | -US$118m |
| Oct 31 2021 | n/a | n/a | -US$80m |
| Jul 31 2021 | n/a | n/a | -US$50m |
| Apr 30 2021 | n/a | n/a | -US$32m |
| Jan 31 2021 | US$6m | US$419k | -US$27m |
| Oct 31 2020 | n/a | n/a | -US$23m |
| Jul 31 2020 | n/a | n/a | -US$19m |
| Apr 30 2020 | n/a | n/a | -US$83m |
| Jan 31 2020 | US$10m | US$346k | -US$91m |
| Oct 31 2019 | n/a | n/a | -US$102m |
| Jul 31 2019 | n/a | n/a | -US$113m |
| Apr 30 2019 | n/a | n/a | -US$54m |
| Jan 31 2019 | US$510k | US$300k | -US$45m |
Compensation vs Market: Chaim's total compensation ($USD8.27M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Chaim's compensation has increased whilst the company is unprofitable.
CEO
Chaim Indig (44 yo)
19.8yrs
Tenure
US$8,273,307
Compensation
Mr. Chaim Indig co-founded Phreesia, Inc. in January 2005 and serves as Chief Executive Officer and Director since January 2005. Mr. Indig has helped to revolutionize the patient check-in experience. Under...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$8.27m | 2.25% $ 24.1m | |
| Co-Founder & COO | 19.8yrs | US$4.50m | 1.3% $ 14.0m | |
| Chief Financial Officer | 1.7yrs | US$5.91m | 0.17% $ 1.8m | |
| General Counsel & Secretary | 4.3yrs | US$3.04m | 0.082% $ 878.9k | |
| Senior Vice President of Life Sciences | 5.7yrs | US$4.47m | 0.36% $ 3.9m | |
| VP & Principal Accounting Officer | less than a year | no data | no data | |
| Chief Technology Officer | less than a year | no data | no data | |
| Vice President of Corporate Communications | 3.8yrs | no data | no data | |
| Vice President of Sales & Marketing Operations | no data | no data | no data | |
| Senior Vice President of Human Resources | 14.6yrs | no data | 0.21% $ 2.2m | |
| Chief Clinical Officer | 3.6yrs | no data | no data | |
| Chief Privacy Officer | 1.4yrs | no data | no data |
3.8yrs
Average Tenure
44yo
Average Age
Experienced Management: PHR's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 19.8yrs | US$8.27m | 2.25% $ 24.1m | |
| Board Observer | no data | no data | no data | |
| Independent Director | 17.1yrs | US$232.46k | 0.065% $ 697.5k | |
| Independent Chairman | 19.8yrs | US$384.98k | 0.57% $ 6.2m | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 5.5yrs | US$257.46k | 0.018% $ 189.5k | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$244.98k | 0.011% $ 113.4k |
17.1yrs
Average Tenure
62yo
Average Age
Experienced Board: PHR's board of directors are seasoned and experienced ( 17.1 years average tenure).